OTLK (Outlook Therapeutics) General and Admin. Expense: $38.12 Mil (TTM As of Mar. 2026)


OTLK Outlook Therapeutics Inc OTLK
11 GF Score
Price $1.48
! 6 Warning Signs
View Full Analysis

What is Outlook Therapeutics General and Admin. Expense?

Outlook Therapeutics OTLK -7.84% 11 General and Admin. Expense is $38.12 Mil as of Mar. 2026. GuruFocus rates OTLK with a GF Score™ of 11/100. The stock has 6 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Outlook Therapeutics's General and Admin. Expense for the three months ended in Mar. 2026 was $9.51 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $38.12 Mil.

Outlook Therapeutics General and Admin. Expense Related Terms

Outlook Therapeutics General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Outlook Therapeutics's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Outlook Therapeutics General and Admin. Expense Chart

Outlook Therapeutics Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.77 20.74 26.67 29.94 39.94

Outlook Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.99 9.68 10.33 8.61 9.51
OTLK
11GF Score
Outlook Therapeutics Inc OTLK
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Outlook Therapeutics General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $38.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of $38.12 Mil mean?
Outlook Therapeutics (OTLK) has a General and Admin. Expense of $38.12 Mil as of Mar. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Outlook Therapeutics and its competitors.
Is Outlook Therapeutics' General and Admin. Expense too high?
Outlook Therapeutics' current General and Admin. Expense is $38.12 Mil. Overall, Outlook Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Outlook Therapeutics' General and Admin. Expense compare to FULC and OBIO?
Outlook Therapeutics' General and Admin. Expense of $38.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Outlook Therapeutics and its competitors. Outlook Therapeutics's current General and Admin. Expense is $38.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Outlook Therapeutics stock overvalued right now?
Outlook Therapeutics (OTLK) has a current General and Admin. Expense of $38.12 Mil. The current General and Admin. Expense is $38.12 Mil. Outlook Therapeutics' overall GF Score™ is 11/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Outlook Therapeutics (OTLK), the current General and Admin. Expense is $38.12 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Outlook Therapeutics Business Description

Other Exchanges 41O:Germany
Address 111 S. Wood Avenue, Suite 100, Iselin, NJ, USA, 08852
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
11GF Score

Get the complete analysis for OTLK

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.48
Price